Canadian Urological Association Journal · 2023 · 11 citations · 18 references
Veterinary MedicineInfectious DiseasesUrologyImmunizationInfection PreventionVaccinologyRecurrent Urinary Tract InfectionUrinary Tract Infection PreventionUrinary Tract InfectionsVaccinationVaccine EffectivenessVaccine EfficacyBacterial Vaccine AntigensHuman VaccinationPatient Satisfaction AnalysisPatient Satisfaction EvaluationPrevention Of Recurrent InfectionRecurrent Urinary Tract Infection ProphylaxisSublingual VaccinationVaccination Efficacy
INTRODUCTION: This is the first North American clinical evidence for MV140, a novel bacterial sublingual vaccine, developed for prevention of recurrent urinary tract infection (UTI) in women. METHODS: Female subjects with ≥3 documented UTIs/year underwent three-month vaccination treatment, nine-month efficacy period, and optional three-month followup (total 15 months). Primary outcome was no clinically diagnosed UTI following vaccination (UTI-free rate). Secondary outcomes included absolute, mean, and median overall reduction in UTI compared to pre-vaccination, quality of life, global response assessment, patient satisfaction, microbiology, and safety. RESULTS: Sixty-seven subjects (mean age 56 years, range 18-80) were enrolled; 64 completed the vaccination period and at least one post-vaccination assessment. Prior to vaccination, subjects reported a mean 6.8 UTIs/year. The UTI-free rate for the nine-month efficacy period was 40.6%. Compared to the infection rate in the year prior to vaccination, the reduction was 75.3% for the nine-month efficacy period post-vaccination. At 12-month followup, 80.3% reported that they were moderately/markedly improved; 58.1% were mostly satisfied, pleased, or delighted, while mean quality of life score improved by 1.5 points. Fourteen of the adverse events in nine subjects were potentially related to the vaccine - all mild and resolved by three months. None of the 13 serious adverse events were related to vaccine. CONCLUSIONS: This first-in-North-America, prospective case series with the sublingual vaccine, MV140, adds further clinical evidence to its safety and effectiveness in reducing recurrent UTIs in women.
18
The MOS 36-ltem Short-Form Health Survey (SF-36)
John E. Ware, Cathy D. Sherbourne · Medical Care · 1992 · 29.8K citations
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
Jennifer T. Anger, Una Lee, Roger Chou et al. · The Journal of Urology · 2019 · 468 citations
Real-World Evidence — Where Are We Now?
John Concato, Jacqueline Corrigan‐Curay · New England Journal of Medicine · 2022 · 206 citations
Florian Wagenlehner, Björn Wullt, Stefania Ballarini et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2017 · 201 citations
Medicine, Internal Medicine, Urology +16